Loading...
•
Mar 31, 2023
Immunome Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
Key Takeaways
Immunome reported its Q1 2023 financial results, highlighting the external validation of its Discovery Engine through the collaboration with AbbVie and the formation of an Antibody-Drug Conjugate and T Cell Redirection Advisory Board.
External validation of Discovery Engine through AbbVie collaboration.
Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board.
Focus on prioritizing novel targets for ADCs and TCRs.
Leveraging Discovery Engine within existing oncology pipeline and strategic collaborations.
Immunome
Immunome
Forward Guidance
The press release contains forward-looking statements regarding Immunome’s ability to achieve anticipated discovery, development and commercial milestones; the timing and results of preclinical studies and clinical trials; regulatory submissions and actions; translation of preclinical data into clinical safety and efficacy; and therapeutic potential and benefits of, and possible need and demand for, Immunome’s programs and development candidates.